CELGENE CORPORATION (NASDAQ:CELG) Files An 8-K Results of Operations and Financial Condition
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On January7, 2019, Celgene Corporation (the “Company”) provided a business update and financial guidance for 2019 at the 37th Annual J.P. Morgan Healthcare Conference. The business update and financial guidance is included in the attached press release, which is incorporated herein by reference. The Company expects to report its 2018 fourth-quarter and full-year financial results on Thursday, January31, 2019.
The information in this Current Report on Form8-K, including the exhibit attached hereto, is furnished solely to Item 2.02 of Form8-K and shall not be deemed “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. Furthermore, the information in this Current Report on Form8-K, including the exhibit attached hereto, shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
Exhibit99.1 — Press Release dated January7, 2019
This exhibit is furnished to Item 2.02 and shall not be deemed to be “filed.”
EXHIBITINDEX
|
ExhibitNo. |
Description |
|
99.1 |
Press Release dated January7, 2019 |
CELGENE CORP /DE/ Exhibit
EX-99.1 2 a19-1334_1ex99d1.htm EX-99.1 Exhibit 99.1 CELGENE CORPORATION ANNOUNCES 2019 FINANCIAL GUIDANCE AND KEY MILESTONES · Company achieved its latest full-year 2018 guidance; will report Q4 2018 results on January 31,…
To view the full exhibit click here
About CELGENE CORPORATION (NASDAQ:CELG)
Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company’s clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology.
